Status:
WITHDRAWN
Stem Cell Therapy in Mental Retardation
Lead Sponsor:
Neurogen Brain and Spine Institute
Conditions:
Mental Retardation
Eligibility:
All Genders
6-40 years
Phase:
PHASE1
Brief Summary
The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.
Eligibility Criteria
Inclusion
- diagnosed cases of mental retardation
- age above 6 months
Exclusion
- presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus
- malignancies
- bleeding tendencies
- pneumonia
- renal failure
- severe liver dysfunction
- severe anemia \[Hemoglobin \< 8\]
- any bone marrow disorder
- space occupying lesion in brain
- other acute medical conditions such as respiratory infection and pyrexia
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02245724
Start Date
September 1 2011
End Date
September 1 2016
Last Update
October 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurogen brain and spine institute
Navi Mumbai, Maharashtra, India